SYDNEY - Kazia Therapeutics Limited (NASDAQ: KZIA), an Australian oncology-focused drug development company, announced the addition of Mr. Robert Apple (NASDAQ:AAPL) as a Non-Executive Director to its Board. The company also appointed Mr. Bryce Carmine as Chairman, succeeding his role as a Director since 2015.
Mr. Apple's career spans over 25 years in the pharmaceutical industry, with significant leadership roles including President and CEO of Antares Pharma (NASDAQ:ATRS), Inc. until its acquisition by Halozyme (NASDAQ:HALO) Therapeutics in 2022. His previous experience includes senior positions at InKine Pharmaceutical and Antares, where he also served as Senior Vice President, CFO, and Corporate Secretary.
The new Chairman, Mr. Carmine, brings extensive experience from Eli Lilly & Co (NYSE:LLY)., where he held various leadership roles, including Executive Vice President and President for Lilly Bio-Medicines. His tenure at Lilly also saw him leading the Global Pharmaceutical Sales and Marketing division.
Dr. John Friend, CEO of Kazia, expressed confidence in the appointments, highlighting the valuable expertise and leadership experience both individuals bring to the Board. The appointments come as Kazia aims to enhance oversight and stewardship during a growth phase.
Kazia's lead drug, paxalisib, targets multiple forms of brain cancer and has shown promising clinical activity. The company anticipates final data from the pivotal GBM AGILE study in the first half of CY2024. Paxalisib has received Orphan Drug and Fast Track Designations for glioblastoma, as well as Rare Pediatric Disease Designation for DIPG, from the US FDA.
Additionally, Kazia is developing EVT801, a VEGFR3 inhibitor, with a Phase I study in advanced solid tumors initiated in November 2021.
The company has cautioned that forward-looking statements involved in this announcement are based on current expectations and projections, subject to risks and uncertainties that could affect actual outcomes.
This news article is based on a press release statement from Kazia Therapeutics Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.